← Back to Search

CAR T-cell Therapy

CART-TnMUC1 for Non-Small Cell Lung Cancer

Phase 1
Waitlist Available
Research Sponsored by Gilead Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 15 years
Awards & highlights

Study Summary

This trial is testing a new cancer treatment involving genetically modified T cells. The goal is to see if it is safe and effective.

Eligible Conditions
  • Non-Small Cell Lung Cancer
  • Multiple Myeloma
  • Breast Cancer
  • Ovarian Cancer
  • Pancreatic Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 15 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 15 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Cohort Expansion: Objective Response in solid tumors
Dose Escalation: Dose Identification of CART-TnMUC1
Secondary outcome measures
Feasibility of CART-TnMUC1 in solid tumors and multiple myeloma
Multiple Myeloma
Preliminary anti-tumor efficacy of CART as assessed by Clinical Benefit Rate in solid tumors
+9 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Dose Escalation Arm1: Solid TumorsExperimental Treatment3 Interventions
Intravenous CART-TnMUC1 cells for patients with TnMUC1+ treatment-resistant ovarian cancer (including cancers of the fallopian tube), pancreatic ductal adenocarcinoma, hormone receptor (HR)-negative and human epidermal growth factor receptor 2 (HER2)-negative (triple negative) breast cancer and non-small cell lung cancer
Group II: Dose Escalation Arm 2: Multiple MyelomaExperimental Treatment3 Interventions
Intravenous CART-TnMUC1 cells for patients with TnMUC1+ relapsed/refractory multiple myeloma
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cyclophosphamide
1995
Completed Phase 3
~3770
Fludarabine
2012
Completed Phase 3
~1100

Find a Location

Who is running the clinical trial?

Gilead SciencesLead Sponsor
1,083 Previous Clinical Trials
843,343 Total Patients Enrolled
Tmunity TherapeuticsLead Sponsor
6 Previous Clinical Trials
133 Total Patients Enrolled
Kite, A Gilead CompanyLead Sponsor
43 Previous Clinical Trials
3,640 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there a cap on the amount of participants enrolled in this experiment?

"At this point, no patients are being accepted into the trial. Its initial post date was October 10th 2019 and it has been most recently updated on July 18 2022. If you're looking to join other studies, there are 2307 trials recruiting individuals with multiple myeloma and 889 trials welcoming participants for CART-TnMUC1 treatments."

Answered by AI

Has the CART-TnMUC1 treatment been endorsed by the FDA?

"The safety of CART-TnMUC1 has not yet been widely studied or established, so it was rated a 1 on the scale. This is because this research is currently in phase one, meaning there are limited data points concerning its efficacy and security."

Answered by AI

For what conditions is CART-TnMUC1 most frequently prescribed?

"CART-TnMUC1 is an accepted treatment for multiple sclerosis, and has also been effectively utilized to address mixed-cell type lymphoma, leukemia, myelocytic acute cancers, and retinoblastomas."

Answered by AI

What are the desired effects of this trial?

"The primary objective of this research, which will be tracked over the course of 2 years, is to expand cohorts with an objective response in solid tumors. Secondary outcomes include the feasibility and tolerability of CART-TnMUC1 cells in both solid tumors and multiple myeloma as well as preliminary anti-tumor efficacy measured by progression free survival (PFS) based on RECIST v1.1 criteria for solid tumors or IMWG criteria for multiple myeloma patients."

Answered by AI

What is the geographic scope of this research initiative?

"10 medical centres are currently participating in this trial, which have been placed strategically near Nashville, Houston and Phoenix. To reduce transportation costs associated with the study, patients should consider enrolling at a clinic nearby them."

Answered by AI

Is there an ongoing recruitment process for participation in this trial?

"Unfortunately, this particular experiment is no longer recruiting. It was initially posted in October 2019 and finalized on July 18th 2022. Fortunately, there are many other studies available with 2307 multiple myeloma trials, as well as 889 CART-TnMUC1 research projects actively seeking participants."

Answered by AI

Are there any prior experiments that have utilized CART-TnMUC1 in the past?

"Currently, there are 889 CART-TnMUC1 trials in progress with 161 being tested during Phase 3. Of the 28443 sites offering these studies, many of them can be found within Philadelphia and Pennsylvania."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers
2019. "A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04025216.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top